Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
INBX

INBX - Inhibrx, Inc. Stock Price, Fair Value and News

15.50USD+0.36 (+2.38%)Market Closed

Market Summary

INBX
USD15.50+0.36
Market Closed
2.38%

INBX Alerts

  • 2 major insider sales recently.

INBX Stock Price

View Fullscreen

INBX RSI Chart

INBX Valuation

Market Cap

812.2M

Price/Earnings (Trailing)

-3

Price/Sales (Trailing)

68.16

EV/EBITDA

-3.16

Price/Free Cashflow

-3.66

INBX Price/Sales (Trailing)

INBX Profitability

EBT Margin

-2261.63%

Return on Equity

-2.3K%

Return on Assets

-93.96%

Free Cashflow Yield

-27.34%

INBX Fundamentals

INBX Revenue

Revenue (TTM)

11.9M

Rev. Growth (Yr)

33.06%

Rev. Growth (Qtr)

9.86%

INBX Earnings

Earnings (TTM)

-271.2M

Earnings Growth (Yr)

-60.91%

Earnings Growth (Qtr)

15.91%

Breaking Down INBX Revenue

Last 7 days

9.2%

Last 30 days

-54.6%

Last 90 days

-55.8%

Trailing 12 Months

-40.9%

How does INBX drawdown profile look like?

INBX Financial Health

Current Ratio

3.82

Debt/Equity

17.68

Debt/Cashflow

-1.06

INBX Investor Care

Shares Dilution (1Y)

20.14%

Diluted EPS (TTM)

-5.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20233.7M5.3M8.6M11.9M
20227.3M5.5M3.8M2.1M
202112.9M10.5M7.2M7.2M
202013.1M13.0M13.0M12.9M
201900013.2M

Tracking the Latest Insider Buys and Sells of Inhibrx, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 30, 2024
viking global investors lp
sold
-214,525,000
30.00
-7,150,830
-
May 30, 2024
eckelman brendan p.
back to issuer
-52,066,600
30.00
-1,735,550
chief scientific officer
May 30, 2024
eckelman brendan p.
back to issuer
-4,800,000
30.00
-160,000
chief scientific officer
May 30, 2024
kayyem jon faiz
back to issuer
-750,000
30.00
-25,000
-
May 30, 2024
kayyem jon faiz
back to issuer
-96,729,000
30.00
-3,224,300
-
May 30, 2024
lappe mark
back to issuer
-74,585,800
30.00
-2,486,190
chief executive officer
May 30, 2024
lappe mark
back to issuer
-15,000,000
30.00
-500,000
chief executive officer
May 30, 2024
lappe mark
back to issuer
-1,783,860
30.00
-59,462
chief executive officer
May 30, 2024
forsyth douglas
back to issuer
-17,947,700
30.00
-598,257
-

1–10 of 50

Which funds bought or sold INBX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
unchanged
-
-99.00
851
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
2,000
918,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.44
110,346
318,346
0.04%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.41
-89,849
789,851
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-30.65
-522,010
919,938
-%
May 15, 2024
SPHERA FUNDS MANAGEMENT LTD.
sold off
-100
-8,608,940
-
-%
May 15, 2024
Soleus Capital Management, L.P.
added
1,685
8,794,770
9,364,770
0.70%
May 15, 2024
TWO SIGMA ADVISERS, LP
added
33.78
1,848,320
9,858,720
0.02%
May 15, 2024
AQR Arbitrage LLC
new
-
3,418,180
3,418,180
0.12%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
added
892
2,440,660
2,740,860
0.01%

1–10 of 42

Are Funds Buying or Selling INBX?

Are funds buying INBX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own INBX
No. of Funds

Unveiling Inhibrx, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 03, 2024
viking global investors lp
0.0%
0
SC 13G/A
Feb 14, 2024
eckelman brendan p.
4.3%
2,035,553
SC 13G/A
Feb 14, 2024
kayyem jon faiz
7.0%
3,308,123
SC 13G/A
Feb 14, 2024
lappe mark
5.2%
2,486,192
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
9.99%
4,724,352
SC 13G/A
Feb 14, 2024
perceptive advisors llc
9.9%
4,776,306
SC 13G/A
Feb 14, 2024
viking global investors lp
15.1%
7,150,826
SC 13G/A
Jan 29, 2024
blackrock inc.
5.7%
2,715,672
SC 13G/A
Jan 23, 2024
state street corp
3.46%
1,635,726
SC 13G/A
Mar 09, 2023
inhibrx, inc.
5.8%
2,512,252
SC 13G/A

Recent SEC filings of Inhibrx, Inc.

View All Filings
Date Filed Form Type Document
Jun 10, 2024
15-12G
15-12G
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
SC 13G/A
Major Ownership Report
May 31, 2024
4
Insider Trading
May 30, 2024
S-8 POS
Employee Benefits Plan
May 30, 2024
S-8 POS
Employee Benefits Plan
May 30, 2024
S-8 POS
Employee Benefits Plan
May 30, 2024
S-8 POS
Employee Benefits Plan
May 30, 2024
POSASR
POSASR
May 30, 2024
8-K
Current Report

Peers (Alternatives to Inhibrx, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
52.5B
6.8B
-17.75% 15.65%
-8.8
7.67
-64.45% -224.75%
28.2B
2.0B
50.83% 15.66%
-84.89
14.07
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
12.78% -8.91%
78.71
6.54
13.74% 186.89%
14.3B
3.8B
11.22% 2.07%
19.2
3.8
8.58% 129.81%
MID-CAP
4.7B
524.1M
-5.39% -54.95%
-11.17
8.9
394.93% 39.61%
4.3B
107.9M
-17.68% 46.87%
-7.87
48.09
54.84% -28.31%
3.7B
251.0M
4.40% -10.91%
-12.58
14.85
73.58% -86.73%
3.4B
240.7M
9.49% -22.70%
-7.15
12.77
-1.03% -213.92%
2.6B
813.8M
4.41% -35.25%
-1.5K
3.22
56.43% 98.83%
2.0B
996.6M
-9.61% 109.10%
-4.93
1.97
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.09% 16.96%
27.9
4.42
60.38% -34.49%
464.6M
881.7K
-3.44% 394.54%
-13.76
481.06
-77.61% 33.36%
206.5M
4.2M
-27.55% 54.46%
-1.65
49.65
-66.30% 48.24%
18.0M
2.1M
-4.57% 211.94%
-0.78
7.61
-13.45% 69.54%

Inhibrx, Inc. News

Latest updates
Defense World13 Jun 202408:52 pm
Simply Wall St13 May 202407:00 am

Inhibrx, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Revenue9.9%3,304,0003,007,3332,710,6672,414,0002,483,000156,000278,000603,500929,0002,856,0002,532,000954,000889,0002,776,0005,901,0003,339,000872,0001,045,5001,219,000
Operating Expenses-17.9%73,825,00089,923,00045,946,00041,369,00043,783,00035,774,00030,281,00035,308,00029,946,00022,260,00021,333,00020,755,00019,447,00019,883,00021,459,00020,506,00018,483,000-14,266,000
  S&GA Expenses27.3%9,974,0007,832,0007,889,0007,263,0006,397,0005,323,0005,347,0005,402,0005,051,0003,645,0002,848,0002,853,0003,009,0002,215,0001,622,0001,532,0001,467,000-1,481,000
  R&D Expenses-22.2%63,851,00082,091,00038,057,00034,106,00037,386,00030,451,00024,934,00029,906,00024,895,00018,615,00018,485,00017,902,00016,438,00017,668,00019,837,00018,974,00017,016,000-12,785,000
EBITDA Margin-14.0%-20.27-17.77-17.49-21.29-31.71-63.12-30.10-18.59-12.07-10.60-10.45-7.10-------
Interest Expenses----6,672,0006,276,0005,256,0003,859,0002,473,0001,502,0001,888,000679,000725,000597,000332,000133,000-39,000--
Income Taxes100.0%--4,0002,0005,000--1,000-4,000----2,0003,000----900,000
Earnings Before Taxes14.4%-78,710,000-91,974,000-51,787,000-47,047,000-48,916,000-40,916,000-35,325,000-37,728,000-31,254,000-21,189,000-20,580,000-20,710,000-19,287,000-17,646,000-20,010,000-17,885,000-20,093,000--19,263,000
EBT Margin-12.4%-22.62-20.12-19.95-24.62-35.92-70.02-32.97-20.00-12.89-11.31-10.94-7.38-------
Net Income15.9%-78,710,000-93,604,000-51,789,000-47,052,000-48,916,000-40,915,000-35,325,000-37,732,000-31,254,000-21,189,000-20,580,000-20,710,000-19,289,000-17,649,000-20,497,000-17,885,000-20,093,000-16,305,000-20,163,000
Net Income Margin-12.3%-22.75-20.25-19.95-24.62-35.92-70.02-32.97-20.00-12.89-11.31-10.94-7.43-------
Free Cashflow-6.5%-64,169,000-60,263,000-55,056,000-42,616,000-39,967,000-30,867,000-30,818,000-27,244,000-27,058,000-22,887,000-13,844,000-22,794,000-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets-6.3%28930837321325429116519316115012914212514414426.00
  Current Assets-7.0%27529536320324428015418215013911913111313213216.00
    Cash Equivalents-9.1%25327833719323427414617614313111312610812912812.00
  Net PPE8.5%7.006.003.003.002.003.003.003.003.003.003.003.003.003.003.003.00
Liabilities4.8%27726424323823923320019813498.0010198.0064.0068.0052.0061.00
  Current Liabilities27.6%72.0056.0036.0031.0033.0028.0025.0024.0020.0022.0025.0022.0028.0031.0035.0021.00
  Long Term Debt-1.2%205207--------------
    LT Debt, Current-4.00--------------4.00
    LT Debt, Non Current-1.2%205207--------------
Shareholder's Equity-73.4%12.0044.00130-15.0058.00--27.0052.0028.0044.0061.0075.0092.00-
  Retained Earnings-12.8%-692-613-520-468-421-372-331-296-258-227-206-185-164-145-127-69.25
  Additional Paid-In Capital7.1%704657650444436430296291286280234230225221219-24.32
Shares Outstanding3.9%49.0047.0047.0044.0044.0044.0039.0039.0039.0039.0038.0038.00----
Float----893---331---764----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q3
Cashflow From Operations-11.0%-63,050-56,821-54,245-42,299-39,944-30,600-30,838-26,922-26,941-22,620-13,675-22,380-21,648-15,389-13,882-11,309-7,388--
  Share Based Compensation-0.5%6,3976,4276,5306,2535,6365,3554,6915,2965,1084,1833,4933,9513,4211,3731,3031,2591,088--
Cashflow From Investing67.5%-1,119-3,442-811-317-23.00-26720.00-322-117-267-169-359-14.00-612-299-362-91.00--
Cashflow From Financing4403.3%38,728860199,891854356158,65950660,16239,22441,48482040,47798816,996136,21816,875-3,633--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

INBX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 0$ 17
Operating expenses:  
Research and development63,85137,386
General and administrative9,9746,397
Total operating expenses73,82543,783
Loss from operations(73,825)(43,766)
Other income (expense):  
Interest expense(8,130)(7,563)
Interest income3,3042,483
Other expense, net(59)(70)
Total other expense(4,885)(5,150)
Loss before income tax expense(78,710)(48,916)
Provision for income taxes00
Net loss$ (78,710)$ (48,916)
Net loss per share, basic (in dollars per share)$ (1.44)$ (1.12)
Net loss per share, diluted (in dollars per share)$ (1.44)$ (1.12)
Weighted-average shares of common stock and pre-funded warrants outstanding, basic (in shares)54,55443,575
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted (in shares)54,55443,575
License fee revenue  
Revenue:  
Total revenue$ 0$ 17

INBX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 252,483$ 277,924
Accounts receivable171171
Other receivables2,867607
Prepaid expenses and other current assets19,01716,656
Total current assets274,538295,358
Property and equipment, net6,9666,419
Operating right-of-use asset2,4872,952
Other non-current assets4,5863,164
Total assets288,577307,893
Current liabilities:  
Accounts payable14,79210,954
Accrued expenses51,32943,295
Current portion of long-term debt, net of discount3,6320
Current portion of operating lease liability2,1172,063
Total current liabilities71,87056,312
Long-term debt, including debt discount and final payment fee204,578206,968
Non-current portion of operating lease liability5611,110
Total liabilities277,009264,390
Commitments and contingencies (Note 7)
Stockholders’ equity  
Preferred stock, $0.0001 par value; 15,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding as of March 31, 2024 and December 31, 2023.00
Common stock, $0.0001 par value; 120,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 49,234,225 and 47,369,511 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.55
Additional paid-in-capital704,007657,232
Accumulated deficit(692,444)(613,734)
Total stockholders’ equity11,56843,503
Total liabilities and stockholders’ equity$ 288,577$ 307,893
INBX
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.
 CEO
 WEBSITEhttps://inhibrx.com
 INDUSTRYBiotechnology
 EMPLOYEES132

Inhibrx, Inc. Frequently Asked Questions


What is the ticker symbol for Inhibrx, Inc.? What does INBX stand for in stocks?

INBX is the stock ticker symbol of Inhibrx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inhibrx, Inc. (INBX)?

As of Mon Jun 24 2024, market cap of Inhibrx, Inc. is 812.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INBX stock?

You can check INBX's fair value in chart for subscribers.

What is the fair value of INBX stock?

You can check INBX's fair value in chart for subscribers. The fair value of Inhibrx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inhibrx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INBX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inhibrx, Inc. a good stock to buy?

The fair value guage provides a quick view whether INBX is over valued or under valued. Whether Inhibrx, Inc. is cheap or expensive depends on the assumptions which impact Inhibrx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INBX.

What is Inhibrx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jun 24 2024, INBX's PE ratio (Price to Earnings) is -3 and Price to Sales (PS) ratio is 68.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INBX PE ratio will change depending on the future growth rate expectations of investors.